Agilent enters agreement to buy Philadelphia-based Proscia for up to $270M
Agilent Technologies entered into a definitive agreement to acquire Philadelphia-based digital pathology software provider Proscia for $240 million in cash plus up to $30 million in performance-based consideration, Pennsylvania Business Report reported. The companies said the deal is expected to close early in Agilent’s fiscal 2027, subject to customary closing conditions.
Agilent — a California-based analytical and clinical laboratory technologies company — agreed to purchase Philadelphia-based Proscia, the companies told Pennsylvania Business Report. Agilent said the acquisition will strengthen its pathology instrumentation and reagents leadership, combine AI-enabled synergies with its companion diagnostics business and add a high-margin software business; Proscia co-founder and CEO David West called the agreement an “exciting milestone.” The firms previously signed a multi‑year distribution agreement in 2022.
Report a correction · Editorial standards · Our source directory
ErieBizToday examines this development and its implications for Erie businesses and communities using the linked sources.
Sources
Publication date of the linked source has not been verified. A sourced news brief; no independent staff reporting is implied. Prepared with AI assistance from the linked research; material claims remain attributed in the article.
Related coverage
- Merck pledges $2.9B expansion in Montgomery County, including $550M for ADVANCE robotics and AI R&D
- Barber expands Erie AI pilot alongside contract renewal
- Behrend research supports an Erie AI consultancy
Reader discussion
Join the discussion. Every comment is checked before publication. Community rules and appeals